Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GYS1 | P13807 | 13/20 | 0.73 |
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16224780 | 0.91 | GYS1 (0.70) | GYS1 | |
| SCHEMBL16005091 | 0.88 | GYS1 (0.70) | GYS1MRGPRX4 | |
| SCHEMBL16004985 | 0.87 | GYS1 (0.69) | GYS1MRGPRX4TP53PKMNFKB1 | |
| SCHEMBL16005279 | 0.85 | GYS1 (1.00) | GYS1 | |
| SCHEMBL17505638 | 0.84 | GYS1 (0.69) | GYS1 | |
| SCHEMBL14933727 | 0.84 | GYS1 (1.00) | GYS1 | |
| SCHEMBL16005024 | 0.84 | GYS1 (0.68) | GYS1MRGPRX4TP53PKMNFKB1 | |
| SCHEMBL17505810 | 0.83 | GYS1 (0.71) | GYS1 | |
| SCHEMBL17505746 | 0.82 | GYS1 (0.83) | GYS1 | |
| SCHEMBL17505748 | 0.82 | GYS1 (0.66) | GYS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160137633-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | AJINOMOTO CO., INC. (JP) | 2016-05-19 | — | — | US | disclosed |
| US-9290487-B2 | Pharmaceutical composition for treating diabetes | AJINOMOTO CO., INC. (JP) | 2016-03-22 | — | — | US | disclosed |
| EP-2993167-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES | Ajinomoto Co., Inc. (JP) | 2016-03-09 | — | — | EP | disclosed |
| EP-2993167-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES | Ajinomoto Co., Inc. (JP) | 2016-03-09 | — | — | EP | disclosed |
| US-20160046592-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES | AJINOMOTO CO., INC. (JP) | 2016-02-18 | — | — | US | disclosed |
| US-20140336376-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | AJINOMOTO CO., INC. (JP) | 2014-11-13 | — | — | US | disclosed |
| WO-2014178381-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES | 味の素株式会社 (JP) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014178389-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF DIABETES | 味の素株式会社 (JP) | 2014-11-06 | — | — | WO | disclosed |
| EP-2774917-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | Ajinomoto Co., Inc. (JP) | 2014-09-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336376-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | PPARG, GPR119, GYS2 | GYS1 5/4885MRGPRX4 1513/4885TP53 3718/4885 |
| US-20160137633-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES | PPARG, GPR119, GYS2 | GYS1 5/4885MRGPRX4 1513/4885TP53 3718/4885 |
| US-20160046592-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DIABETES | PPARG, GPR119, PPARA | GYS1 7/4885MRGPRX4 1626/4885TP53 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.